--- title: "FreeStyle Libre CGM — Evidence, Benefits & Where to Buy | Magellan" description: "FreeStyle Libre CGM — The FreeStyle Libre is a factory-calibrated, intermittently scanned (\"flash\") continuous glucose monitor made by Abbott. A small…" url: "https://magellanlongevity.com/p/73.md" canonical: "https://magellanlongevity.com/p/73.html" html: "https://magellanlongevity.com/p/73.html" type: "product" section: "Biometric Wearables & Sensors" evidence_grade: "Measurement tool" evidence_tier: "tool" citations: 20 product_id: 73 price_usd: 139 updated: 2026-09-02 author: "Gabriel Radu, DO" author_credentials: "Physiatrist (PM&R). NY medical license 275110. NPI 1376861765." publisher: "Magellan Longevity" content_format: "markdown" license: "Educational content — not medical advice" --- # FreeStyle Libre CGM [Home](https://magellanlongevity.com/) › [Biometric Wearables & Sensors](https://magellanlongevity.com/c/4.md) › FreeStyle Libre CGM **HTML version:** https://magellanlongevity.com/p/73.html · **In the Magellan app:** https://magellanlongevity.com/#/product/73 ## Key facts | Field | Value | | --- | --- | | Product | FreeStyle Libre CGM | | Category | [Biometric Wearables & Sensors](https://magellanlongevity.com/c/4.md) | | Evidence grade | Measurement tool (B) | | Peer-reviewed citations | 20 | | Typical listed price | $139.00 (check the live price) | | Where to buy | [Search Amazon](https://www.amazon.com/s?k=FreeStyle%20Libre%20CGM&tag=magellanlong-20) | | Catalog ID | 73 | ## What it is The FreeStyle Libre is a factory-calibrated, intermittently scanned ("flash") continuous glucose monitor made by Abbott. A small sensor worn on the back of the upper arm measures glucose in the interstitial fluid just below the skin and reports current glucose, a trend arrow, and glucose history when scanned or read by a phone, replacing routine fingerstick self-monitoring of blood glucose (SMBG). Beyond a single reading, such devices generate summary metrics like time in range (TIR), time below and above range, and glycemic variability that describe day-to-day glucose control. Since 2024, several CGM systems—including ones built on the Libre platform—have been cleared for over-the-counter sale in the U.S., moving glucose monitoring from a prescription diabetes tool into the consumer wellness space. ## Its role in longevity In randomized trials and meta-analyses, continuous and flash glucose monitoring modestly lowers HbA1c (about 0.2–0.3 percentage points on average) and, more strikingly, cuts time spent in hypoglycemia—by 38% in type 1 diabetes and by roughly half in insulin-treated type 2 diabetes—compared with fingerstick testing; in non-insulin-treated type 2 diabetes it raised time in range by about 10% over education alone. The derived metric time in range is validated against long-term microvascular complications such as retinopathy, giving CGM data prognostic meaning. The caveats matter: HbA1c did not improve in the insulin-treated type 2 trial, most trials were short and open-label, hard-endpoint data are scarce, and regulators have recalled certain sensor lots for inaccurate readings. For people without diabetes—the biohacking use case—evidence is weak: a 2024 meta-analysis of CGM as a behavior-change tool found only modest short-term glycemic changes, driven mostly by participants with diabetes, and no significant effect on weight; no trial shows disease-prevention or lifespan benefit. CGMs are medical tools for diabetes management, not proven longevity interventions; educational, not medical advice. ## Evidence grade: Measurement tool - **What the grade means:** Graded as an instrument: how accurately it measures, and whether measuring it changes anything. - **Dose used in studies:** Treat it as a two-week experiment, not a permanent feed. Test specific questions — how your usual breakfast compares with a higher-protein version, what a 15-minute post-meal walk does to the curve — then take the sensor off. Do not chase a flat line: post-meal rises are normal physiology, and there is no validated target range for people without diabetes. - **What this grade does not say:** Two questions matter for a CGM worn without diabetes, and both answers are uncomfortable. On accuracy: in healthy adolescents the Libre's mean absolute relative difference against fingerstick plasma glucose was 13.1%, with only 68% of paired readings meeting the ISO 15197:2013 criterion, and in children without diabetes it showed magnitude bias at fasting levels and correlated poorly with true fasting glucose (r-squared 0.06) — it is built to track the large swings of diabetes, not to resolve the narrow band a normoglycemic person lives in. On whether measuring changes anything: the meta-analysis of 25 randomized trials of CGM as a behaviour-change tool found a modest HbA1c benefit driven by participants who had diabetes, no significant effect on weight or BMI, and only three trials in people without diabetes. Healthy people already spend roughly 15% of the time in the prediabetic range on CGM, and when 18 expert clinicians were handed non-diabetic CGM reports they could not agree on who needed follow-up — so expect to see spikes, and expect that nobody can currently tell you what they mean. ## In the news - **Flash Continuous Glucose Monitoring (FreeStyle Libre 14-Day System) for Self-Management of Diabetes Mellitus** — American Family Physician 2021 [Read it](https://www.aafp.org/afp/2021/0601/p688) > The use of FreeStyle Libre increases time in euglycemic range and decreases hyperglycemic and hypoglycemic time and events in adults with type 1 diabetes. - **Continuous Glucose Monitors** — Centers for Disease Control and Prevention (CDC) 2025 [Read it](https://www.cdc.gov/diabetes/treatment/continuous-glucose-monitors.html) > Continuous glucose monitors (CGMs) are wearable devices that can help people with diabetes more effectively and easily manage their blood sugar. ## The research Peer-reviewed studies on the active compound. Quotes are verbatim from the cited abstract. Research describes the active mechanism and is not a claim about this specific product. ### Cited studies 1. **Continuous Glucose Monitoring and Physical Activity** International Journal of Environmental Research and Public Health 2022 · [PMID 36231598](https://pubmed.ncbi.nlm.nih.gov/36231598/) · [DOI 10.3390/ijerph191912296](https://doi.org/10.3390/ijerph191912296) > Continuous glucose monitoring use has several potential positive effects on management, including increased time in range and optimized therapy. 2. **Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring** J Clin Endocrinol Metab 2022 · [PMID 35094087](https://pubmed.ncbi.nlm.nih.gov/35094087/) · [DOI 10.1210/clinem/dgac034](https://doi.org/10.1210/clinem/dgac034) > higher time in range was associated with reduced cardiovascular and all-cause mortality 3. **Effects of Continuous Glucose Monitoring on Metrics of Glycemic Control in Diabetes: A Systematic Review With Meta-analysis of Randomized Controlled Trials.** Diabetes Care 2020 · [PMID 32312858](https://pubmed.ncbi.nlm.nih.gov/32312858/) · [DOI 10.2337/dc19-1459](https://doi.org/10.2337/dc19-1459) > CGM improves glycemic control by expanding TIR and decreasing TBR, TAR, and glucose variability in both type 1 and type 2 diabetes. 4. **Effectiveness of Continuous Glucose Monitoring on Metrics of Glycemic Control in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.** J Clin Endocrinol Metab 2024 · [PMID 37987208](https://pubmed.ncbi.nlm.nih.gov/37987208/) · [DOI 10.1210/clinem/dgad652](https://doi.org/10.1210/clinem/dgad652) > Both rt-CGM and flash CGM led to modest but statistically significant declines in HbA1c among individuals with T2DM, with little heterogeneity in the results. 5. **The Effectiveness of Continuous Glucose Monitoring in Patients with Type 2 Diabetes: A Systematic Review of Literature and Meta-analysis.** Diabetes Technol Ther 2018 · [PMID 30095980](https://pubmed.ncbi.nlm.nih.gov/30095980/) · [DOI 10.1089/dia.2018.0177](https://doi.org/10.1089/dia.2018.0177) > RT-CGM and P-CGM were associated with a modest but statistically significant reduction in HbA1c of 0.20% (95% confidence interval [CI] -0.31 to -0.09) compared with control. Patients who received FGM had a nonsignificant reduction of 0.02% (95% CI -0.07 to 0.04) compared with control. 6. **Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis.** Diabetologia 2024 · [PMID 38363342](https://pubmed.ncbi.nlm.nih.gov/38363342/) · [DOI 10.1007/s00125-024-06107-6](https://doi.org/10.1007/s00125-024-06107-6) > CGM use compared with SMBG is associated with improvements in glycaemic control in adults with type 2 diabetes. However, all studies were open label. In addition, outcome data on incident severe hypoglycaemia and incident microvascular and macrovascular complications were scarce. 7. **Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial.** Diabetologia 2017 · [PMID 29273897](https://pubmed.ncbi.nlm.nih.gov/29273897/) · [DOI 10.1007/s00125-017-4527-5](https://doi.org/10.1007/s00125-017-4527-5) > At 6 months, mean time in hypoglycaemia was reduced by 46.0%, from 3.44 h/day to 1.86 h/day in the intervention group (baseline adjusted mean change, -1.65 h/day) 8. **Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial.** Diabetes Ther 2016 · [PMID 28000140](https://pubmed.ncbi.nlm.nih.gov/28000140/) · [DOI 10.1007/s13300-016-0223-6](https://doi.org/10.1007/s13300-016-0223-6) > Flash glucose-sensing technology use in type 2 diabetes with intensive insulin therapy results in no difference in HbA1c change and reduced hypoglycemia, thus offering a safe, effective replacement for SMBG. 9. **IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial.** Diabetes Obes Metab 2023 · [PMID 36546594](https://pubmed.ncbi.nlm.nih.gov/36546594/) · [DOI 10.1111/dom.14949](https://doi.org/10.1111/dom.14949) > The IMMEDIATE study has shown that among non-insulin-treated individuals with type 2 diabetes, use of isCGM is associated with an improvement in glycaemic outcomes. 10. **Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: A pilot, multicentre, randomised controlled trial.** Diab Vasc Dis Res 2019 · [PMID 31271312](https://pubmed.ncbi.nlm.nih.gov/31271312/) · [DOI 10.1177/1479164119827456](https://doi.org/10.1177/1479164119827456) > Libre Pro can improve HbA1c and treatment satisfaction without increasing hypoglycaemic exposure in insulin-treated type 2 diabetes individuals managed in primary/secondary care centres. 11. **Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial.** JAMA 2020 · [PMID 32543683](https://pubmed.ncbi.nlm.nih.gov/32543683/) · [DOI 10.1001/jama.2020.6940](https://doi.org/10.1001/jama.2020.6940) > Among adolescents and young adults with type 1 diabetes, continuous glucose monitoring compared with standard blood glucose monitoring resulted in a small but statistically significant improvement in glycemic control over 26 weeks. 12. **Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.** Diabetes Care 2018 · [PMID 30352896](https://pubmed.ncbi.nlm.nih.gov/30352896/) · [DOI 10.2337/dc18-1444](https://doi.org/10.2337/dc18-1444) > The hazard rate of development of retinopathy progression was increased by 64% (95% CI 51-78), and development of the microalbuminuria outcome was increased by 40% (95% CI 25-56), for each 10 percentage points lower TIR 13. **The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes.** Diabetes Technol Ther 2018 · [PMID 30575414](https://pubmed.ncbi.nlm.nih.gov/30575414/) · [DOI 10.1089/dia.2018.0310](https://doi.org/10.1089/dia.2018.0310) > There is a good correlation between HbA1C and %TIR that may permit the transition to %TIR as the preferred metric for determining the outcome of clinical studies, predicting of the risk of diabetes complications, and assessing of an individual patient's glycemic control. 14. **Effect of Flash Glucose Monitoring on Glycemic Control, Hypoglycemia, Diabetes-Related Distress, and Resource Utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit.** Diabetes Care 2020 · [PMID 32669277](https://pubmed.ncbi.nlm.nih.gov/32669277/) · [DOI 10.2337/dc20-0738](https://doi.org/10.2337/dc20-0738) > We show that the use of FSL was associated with significantly improved glycemic control and hypoglycemia awareness and a reduction in hospital admissions. 15. **Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4).** BMJ Open Diabetes Res Care 2019 · [PMID 31875133](https://pubmed.ncbi.nlm.nih.gov/31875133/) · [DOI 10.1136/bmjdrc-2019-000809](https://doi.org/10.1136/bmjdrc-2019-000809) > Real world data demonstrate that use of FSL-FGM results in improved well-being and decreased disease burden, as well as improvement of glycemic control. 16. **A review of flash glucose monitoring in type 2 diabetes.** Diabetol Metab Syndr 2021 · [PMID 33836819](https://pubmed.ncbi.nlm.nih.gov/33836819/) · [DOI 10.1186/s13098-021-00654-3](https://doi.org/10.1186/s13098-021-00654-3) > Additional benefits associated with flash glucose monitoring versus SMBG include reductions in acute diabetes events, all-cause hospitalizations and hospitalized ketoacidosis episodes; improved well-being and decreased disease burden; and greater treatment satisfaction. 17. **Cost Calculation for a Flash Glucose Monitoring System for Adults with Type 2 Diabetes Mellitus Using Intensive Insulin - a UK Perspective.** Eur Endocrinol 2018 · [PMID 30349600](https://pubmed.ncbi.nlm.nih.gov/30349600/) · [DOI 10.17925/EE.2018.14.2.86](https://doi.org/10.17925/EE.2018.14.2.86) > flash monitoring would cost an additional £585 per patient per year, offset by a £776 reduction in healthcare resource use, based on reductions in emergency room visits (41%), ambulance call-outs (66%) and hospital admissions (77%) observed in the REPLACE trial. 18. **Combined assessment of stress hyperglycemia ratio and glycemic variability to predict all-cause mortality in critically ill patients with atherosclerotic cardiovascular diseases across different glucose metabolic states: an observational cohort study with machine learning.** Cardiovasc Diabetol 2025 · [PMID 40346649](https://pubmed.ncbi.nlm.nih.gov/40346649/) · [DOI 10.1186/s12933-025-02762-0](https://doi.org/10.1186/s12933-025-02762-0) > Combined SHR and GV assessment serves as a critical prognostic tool for ASCVD mortality, providing enhanced predictive accuracy compared to individual metrics, particularly in NGR and Pre-DM patients. 19. **Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial.** Lancet (London, England) 2016 · [PMID 27634581](https://pubmed.ncbi.nlm.nih.gov/27634581/) > In this 241-patient RCT, flash glucose monitoring cut time spent in hypoglycemia by 38% versus fingerstick self-monitoring in adults with well-controlled type 1 diabetes. 20. **The efficacy of using continuous glucose monitoring as a behaviour change tool in populations with and without diabetes: a systematic review and meta-analysis of randomised controlled trials.** The international journal of behavioral nutrition and physical activity 2024 · [PMID 39716288](https://pubmed.ncbi.nlm.nih.gov/39716288/) > Across 25 RCTs (n=2,996), CGM as a behavior-change tool produced modest glycemic improvements (HbA1c −0.28%, time in range +7.4%), driven mostly by participants with diabetes, with no significant effect on weight or BMI. ## Where to buy [Search Amazon for FreeStyle Libre CGM](https://www.amazon.com/s?k=FreeStyle%20Libre%20CGM&tag=magellanlong-20) — affiliate search link. ## Structured data ```json {"@context":"https://schema.org","@graph":[{"@type":"ItemPage","@id":"https://magellanlongevity.com/p/73.html#page","url":"https://magellanlongevity.com/p/73.html","name":"FreeStyle Libre CGM","description":"The FreeStyle Libre is a factory-calibrated, intermittently scanned (\"flash\") continuous glucose monitor made by Abbott. A small sensor worn on the back…","inLanguage":"en","isPartOf":{"@type":"WebSite","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"author":{"@type":"Person","name":"Gabriel Radu, DO","jobTitle":"Physiatrist (PM&R)","identifier":[{"@type":"PropertyValue","name":"NPI","value":"1376861765"},{"@type":"PropertyValue","name":"NY medical license","value":"275110"}]},"publisher":{"@type":"Organization","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"encoding":{"@type":"MediaObject","encodingFormat":"text/markdown","contentUrl":"https://magellanlongevity.com/p/73.md"},"dateModified":"2026-09-02"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://magellanlongevity.com/"},{"@type":"ListItem","position":2,"name":"Biometric Wearables & Sensors","item":"https://magellanlongevity.com/c/4.html"},{"@type":"ListItem","position":3,"name":"FreeStyle Libre CGM","item":"https://magellanlongevity.com/p/73.html"}]},{"@type":"Product","@id":"https://magellanlongevity.com/p/73.html#product","name":"FreeStyle Libre CGM","category":"Biometric Wearables & Sensors","url":"https://magellanlongevity.com/p/73.html","description":"The FreeStyle Libre is a factory-calibrated, intermittently scanned (\"flash\") continuous glucose monitor made by Abbott. A small sensor worn on the back of the upper arm measures glucose in the interstitial fluid just below the skin and reports current glucose, a trend arrow, and glucose history…","additionalProperty":[{"@type":"PropertyValue","name":"Evidence grade","value":"Measurement tool"}],"offers":{"@type":"Offer","priceCurrency":"USD","price":"139.00","url":"https://www.amazon.com/s?k=FreeStyle%20Libre%20CGM&tag=magellanlong-20","availability":"https://schema.org/InStock"}}]} ``` ## Related on Magellan Longevity - [Garmin Forerunner 265](https://magellanlongevity.com/p/65.md) — Across brands, independent validations find these devices agree closely with polysomnography for… - [Oura Ring Gen 4](https://magellanlongevity.com/p/61.md) — Across brands, independent validations find these devices agree closely with polysomnography for… - [Apple Watch Series 11](https://magellanlongevity.com/p/63.md) — Across brands, independent validations find these devices agree closely with polysomnography for… - [WHOOP Band 5.0](https://magellanlongevity.com/p/62.md) — Across brands, independent validations find these devices agree closely with polysomnography for… - [Garmin Vivoactive 6](https://magellanlongevity.com/p/64.md) — Across brands, independent validations find these devices agree closely with polysomnography for… - [All Biometric Wearables & Sensors](https://magellanlongevity.com/c/4.md) - [Evidence-based longevity supplements](https://magellanlongevity.com/longevity-supplements.md) - [Longevity research map](https://magellanlongevity.com/longevity-research-map.html) ## Scope and disclosures Educational information, not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if you are pregnant, nursing, or taking medication. Editorial firewall: evidence grades are assigned from the published research and are independent of any affiliate commission. As an Amazon Associate, Magellan Longevity earns from qualifying purchases. Reviewed for accuracy by a board-certified physician (DO).